Tharimmune to Present at 2024 BIO Convention

Tharimmune, Inc. (NASDAQ:THAR), a clinical-stage biotechnology company, announced that its management team will be presenting at the 2024 BIO International Convention from June 3-6, 2024, in San Diego. During the convention, the company will not only present but also engage in one-on-one meetings with investors and industry leaders.

The specific details for the event are as follows:
- Event: 2024 BIO International Convention
- Date: Monday, June 3, 2024
- Time: 1:45 p.m. Pacific Time
- Location: Company Presentation Theater 3

Those interested in scheduling a meeting with Tharimmune's management at the convention are advised to submit a request via the BIO One-on-One Partnering™ system.

Tharimmune specializes in developing therapeutic candidates focused on inflammation and immunology. Their lead asset, TH104, is currently in clinical stages and is designed to address chronic, debilitating pruritus in Primary Biliary Cholangitis (PBC), a rare liver disease that presently has no known cure. Besides TH104, Tharimmune's early-stage pipeline includes innovative multi-specific antibodies. These antibodies target unique epitopes and employ novel mechanisms of action against well-known targets in various solid tumors, such as PD-1, HER2, and HER3.

Tharimmune has also entered into a license agreement with OmniAb, Inc., granting them access to OmniAb's advanced antibody discovery technology platform, which is crucial for developing therapies against multiple specified targets.

The company's presence at the BIO International Convention underscores its commitment to advancing its therapeutic portfolio and engaging with key stakeholders in the biotechnology and pharmaceutical sectors.